SeraNovo BV based in Leiden, The Netherlands, entered a License Agreement with Équilibre BioPharmaceuticals Corp. in New York, a biopharmaceutical company developing small molecules in the field of neuroscience. Under the agreement, the companies will expand their existing collaboration and jointly develop a breakthrough product.
 
Niall Hodgins, Chief Executive Officer of SeraNovo said, “We are thrilled to enter into this license agreement with Équilibre and progress another poorly water soluble drug candidate into the clinic using our deep eutectic solvent formulation platform. This agreement is a great step to broaden our customer base in North America and into the neurology field. SeraNovo are looking forward to many fruitful collaborations in these important markets.”